DVM,MS Jeonbuk national university, Bon animal hospital Suwon, Kyonggi-do, Republic of Korea
Presentation Description / Summary: Pulmonary hypertension (PH) in dogs remains a challenging condition to manage, particularly when clinical signs such as syncope and exercise intolerance persist despite conventional therapy with phosphodiesterase-5 inhibitors like sildenafil. Beraprost, an oral prostacyclin analog, has been proposed as an adjunctive therapy due to its vasodilatory and antiplatelet effects, but limited clinical data exist regarding its use in veterinary patients.
In this session, we will present clinical findings from mininum 20 dogs with PH treated with beraprost in addition to standard therapy. Across these cases, beraprost administration was well tolerated without significant adverse effects. Notably, when used as an add-on to sildenafil, beraprost was associated with improvement in clinical symptoms, including a reduction in syncopal episodes and improved exercise tolerance. Echocardiographic assessments also demonstrated favorable changes in PH-related indices following therapy.
Through a case-based discussion, attendees will gain practical insights into patient selection, dosing strategies, and monitoring considerations for beraprost in dogs with PH. This presentation aims to highlight the potential clinical benefits of beraprost as part of a multimodal treatment plan, and to encourage further investigation into its role in managing canine pulmonary hypertension.
Learning Objectives:
Upon completion, participants will be able to describe the pharmacologic properties and proposed mechanisms of action of beraprost in the management of canine pulmonary hypertensio
Upon completion, participants will be able to evaluate the clinical indications and patient selection criteria for adding beraprost to standard therapy in dogs with pulmonary hypertension.
Upon completion, participants will be able to interpret case-based clinical outcomes, including echocardiographic indices and clinical signs, in dogs treated with beraprost.
Upon completion, participants will be able to consider the use of beraprost as an adjunct therapy in dogs with refractory pulmonary hypertension unresponsive to conventional treatment.
